









Markets
/
Stocks
/
nasdaq-dxcm
/

Dexcom Inc

DXCM

75.580USD

-0.640-0.84%

Close 09/15, 16:00（ET）Quotes delayed by 15 min

29.64BMarket Cap

51.87P/E TTM



Dexcom Inc

75.580

-0.640-0.84%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-12

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

26 / 207

Overall Ranking

134 / 4724

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 29 analysts

Buy

Current Rating

103.329

Target Price

+35.57%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 38.60% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 68.87.

Undervalued

The company’s latest PE is 52.28, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 390.97M shares, decreasing 6.58% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 48.15M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-12

The company's current financial score is 7.68, which is higher than the Healthcare Equipment & Supplies industry's average of 7.15. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 1.04B, representing a year-over-year increase of 12.49%, while its net profit experienced a year-over-year increase of 28.01%.

Score

Industry at a Glance

Previous score

7.68

Change



Financials

8.77

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.73

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.53

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.24

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-12

The company’s current valuation score is 1.80, which is lower than the Healthcare Equipment & Supplies industry's average of 2.15. Its current P/E ratio is 52.39, which is 16.64% below the recent high of 61.11 and -2.59% above the recent low of 53.74.

Score

Industry at a Glance

Previous score

1.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 26/207

No Data

Earnings Forecast

Currency: USD Updated：2025-09-12

The company’s current earnings forecast score is 8.57, which is higher than the Healthcare Equipment & Supplies industry's average of 7.66. The average price target for Dexcom Inc is 102.00, with a high of 120.00 and a low of 86.22.

Score

Industry at a Glance

Previous score

8.48

Change

Support & Resistance

No Data

Analyst Rating

Based on 29 analysts

Buy

Current Rating

103.329

Target Price

+35.57%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

118

Total

Median

Average

Company name

Ratings

Analysts

Dexcom Inc

DXCM

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Insulet Corp

PODD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-12

The company’s current price momentum score is 6.53, which is lower than the Healthcare Equipment & Supplies industry's average of 7.47. Sideways: Currently, the stock price is trading between the resistance level at 84.01 and the support level at 71.75, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.66

Change

0.04

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.106

Sell

RSI(14)

41.147

Neutral

STOCH(KDJ)(9,3,3)

28.408

Sell

ATR(14)

2.379

High Vlolatility

CCI(14)

-15.105

Neutral

Williams %R

74.174

Sell

TRIX(12,20)

-0.200

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

76.440

Sell

MA10

77.469

Sell

MA20

77.992

Sell

MA50

80.881

Sell

MA100

81.679

Sell

MA200

80.080

Sell

Institutional Confidence

Currency: USD Updated：2025-09-12

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. The latest institutional shareholding proportion is 99.70%, representing a quarter-over-quarter increase of 1.13%. The largest institutional shareholder is The Vanguard, holding a total of 48.15M shares, representing 12.28% of shares outstanding, with 3.47% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

47.29M

+2.01%

BlackRock Institutional Trust Company, N.A.

24.72M

+2.23%

State Street Global Advisors (US)

16.68M

-0.02%

Baillie Gifford & Co.

Star Investors

14.18M

-2.96%

Jennison Associates LLC

10.52M

+37.67%

Geode Capital Management, L.L.C.

10.41M

+4.14%

Sands Capital Management, LLC

Star Investors

10.41M

-6.26%

Invesco Capital Management (QQQ Trust)

8.10M

-0.04%

Nuveen LLC

7.85M

+0.28%

MFS Investment Management

3.19M

+170.89%

Risk Assessment

Currency: USD Updated：2025-09-12

The company's beta value is 1.45. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.